Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Completes Private Placement of Units

NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN);...
January 17, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences

TORONTO and CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
December 18, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek

TORONTO and CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
December 17, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board

TORONTO and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
November 20, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Issues Year-to-Date Update, Highlighting 2018 Accomplishments

TORONTO and CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
November 13, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Third Quarter 2018 Results

TORONTO and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
November 06, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer’s Disease

Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer TORONTO and CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE)...
October 31, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer’s Disease and Other Dementias

ProMIS’ proprietary discovery platform generates additional potential opportunities for pharma partnering TORONTO and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences,...
October 11, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson’s Disease

TORONTO and CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
September 13, 2018 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer

TORONTO and CAMBRIDGE, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...